FTC Reaches Proposed Settlement With CVS Caremark Change The Federal Trade Commission reached a proposed settlement with CVS Caremark over allegations that its pharmacy benefit manager inflated insulin prices and impeded access to the diabetes treatment. Why it matters The FTC filed a document indicating a proposed settlement with CVS Caremark resolving allegations that the company's PBM inflated insulin prices and impeded access. The proposed agreement is subject to review and approval by the FTC chair. CVS has said final terms are pending and expects the settlement process to conclude in the coming weeks. The matter follows a final settlement last month between the FTC and another large PBM, Express Scripts, and originates from an FTC complaint filed in September 2024 against multiple PBMs. STAT · Mar 25 More actions Like (sign in) Save (sign in) Share Facebook LinkedIn X / Twitter Copy link
